{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:51:23Z","timestamp":1784173883176,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"President Foundation of The Fifth Affiliated Hospital, Southern MedicalUniversity","award":["YZ2022QN03"],"award-info":[{"award-number":["YZ2022QN03"]}]},{"name":"Building High-level Hospitals, High-level Clinical Medical Centers and Key Clinical Specialty Projects","award":["[2021] No. 76"],"award-info":[{"award-number":["[2021] No. 76"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1245\/s10434-025-17601-5","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T14:32:07Z","timestamp":1749911527000},"page":"6838-6850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Appraisal of Residual Tumor Burden on Survival Prognosis Following Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: A Multicenter Cohort Study"],"prefix":"10.1245","volume":"32","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Long","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Kang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Ming","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Xian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Ao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"17601_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"17601_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"17601_CR3","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396.","journal-title":"Lancet Oncol"},{"key":"17601_CR4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392.","journal-title":"Lancet Oncol"},{"key":"17601_CR5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof M, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995\u20132004.","journal-title":"J Clin Oncol"},{"key":"17601_CR6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijsu.2018.01.008","volume":"51","author":"F Coccolini","year":"2018","unstructured":"Coccolini F, Nardi M, Montori G, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120\u20137.","journal-title":"Int J Surg"},{"key":"17601_CR7","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313.","journal-title":"J Clin Oncol"},{"key":"17601_CR8","doi-asserted-by":"crossref","first-page":"111352","DOI":"10.1016\/j.intimp.2023.111352","volume":"127","author":"X Huan","year":"2024","unstructured":"Huan X, Zou K, Zhang P, et al. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer. Int Immunopharmacol. 2024;127:111352.","journal-title":"Int Immunopharmacol"},{"key":"17601_CR9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"17601_CR10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"17601_CR11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41:747\u201395.","journal-title":"Cancer Commun (Lond)"},{"key":"17601_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-017-0765-y","volume":"21","author":"H In","year":"2018","unstructured":"In H, Ravetch E, Langdon-Embry M, et al. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018;21:1\u20139.","journal-title":"Gastric Cancer"},{"key":"17601_CR13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1245\/s10434-023-14478-0","volume":"31","author":"Y Wang","year":"2024","unstructured":"Wang Y, Tang L, Ying X, et al. Pre- and post-treatment double-sequential-point dynamic radiomic model in the response prediction of gastric cancer to neoadjuvant chemotherapy: 3-year survival analysis. Ann Surg Oncol. 2024;31:774\u201382.","journal-title":"Ann Surg Oncol"},{"key":"17601_CR14","doi-asserted-by":"crossref","first-page":"108367","DOI":"10.1016\/j.ejso.2024.108367","volume":"50","author":"LK Zhang","year":"2024","unstructured":"Zhang LK, Zheng HL, Zheng HH, et al. Effects of tumor marker regression load score on long-term prognosis of gastric cancer patients undergoing radical surgery after neoadjuvant chemotherapy. Eur J Surg Oncol. 2024;50:108367.","journal-title":"Eur J Surg Oncol"},{"key":"17601_CR15","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1634\/theoncologist.2020-0022","volume":"26","author":"Q Zhong","year":"2021","unstructured":"Zhong Q, Chen QY, Parisi A, et al. Modified ypTNM Staging classification for gastric cancer after neoadjuvant therapy: a multi-institutional study. Oncologist. 2021;26:e99\u2013110.","journal-title":"Oncologist"},{"key":"17601_CR16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10120-017-0779-5","volume":"21","author":"X Ji","year":"2018","unstructured":"Ji X, Bu ZD, Yan Y, et al. The eighth edition of the American Joint Committee on Cancer tumor-node-metastasis staging system for gastric cancer is superior to the 7th edition: results from a Chinese mono-institutional study of 1663 patients. Gastric Cancer. 2018;21:643\u201352.","journal-title":"Gastric Cancer"},{"key":"17601_CR17","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Wiley; 2017."},{"key":"17601_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12885-022-10479-6","volume":"23","author":"R Zhang","year":"2023","unstructured":"Zhang R, Hu C, Zhang J, et al. Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer. BMC Cancer. 2023;23:5.","journal-title":"BMC Cancer"},{"key":"17601_CR19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/SLA.0000000000005977","volume":"279","author":"AF van Oosten","year":"2024","unstructured":"van Oosten AF, Groot VP, Dorland G, et al. Dynamics of serum CA19-9 in patients undergoing pancreatic cancer resection. Ann Surg. 2024;279:493\u2013500.","journal-title":"Ann Surg"},{"key":"17601_CR20","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","volume":"23","author":"HHN Yan","year":"2018","unstructured":"Yan HHN, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23:882-897.e11.","journal-title":"Cell Stem Cell"},{"key":"17601_CR21","doi-asserted-by":"crossref","first-page":"8561","DOI":"10.1245\/s10434-023-14194-9","volume":"30","author":"R Zhang","year":"2023","unstructured":"Zhang R, Chen X, Chen G, et al. Combined use of tumor markers in gastric cancer: a novel method with promising prognostic accuracy and practicality. Ann Surg Oncol. 2023;30:8561\u201371.","journal-title":"Ann Surg Oncol"},{"key":"17601_CR22","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1245\/s10434-018-6634-z","volume":"25","author":"JX Lin","year":"2018","unstructured":"Lin JX, Wang W, Lin JP, et al. Preoperative tumor markers independently predict survival in stage III gastric cancer patients: Should we include tumor markers in AJCC staging? Ann Surg Oncol. 2018;25:2703\u201312.","journal-title":"Ann Surg Oncol"},{"key":"17601_CR23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1096-9098(200007)74:3<185::AID-JSO4>3.0.CO;2-0","volume":"74","author":"DY Kim","year":"2000","unstructured":"Kim DY, Kim HR, Shim JH, et al. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol. 2000;74:185\u201392.","journal-title":"J Surg Oncol"},{"key":"17601_CR24","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3748\/wjg.v26.i19.2427","volume":"26","author":"YH Chen","year":"2020","unstructured":"Chen YH, Xiao J, Chen XJ, et al. Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World J Gastroenterol. 2020;26:2427\u201339.","journal-title":"World J Gastroenterol"},{"key":"17601_CR25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12957-023-03291-4","volume":"22","author":"M Chen","year":"2024","unstructured":"Chen M, Yu S, Chen C, et al. Development and evaluation of the Newstage system: integrating tumor regression grade and lymph node status for improved prognostication in neoadjuvant treatment of gastric cancer. World J Surg Oncol. 2024;22:16.","journal-title":"World J Surg Oncol"},{"key":"17601_CR26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10120-016-0601-9","volume":"20","author":"T Sano","year":"2017","unstructured":"Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20:217\u201325.","journal-title":"Gastric Cancer"},{"key":"17601_CR27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00423-012-1039-0","volume":"398","author":"K Ott","year":"2013","unstructured":"Ott K, Blank S, Becker K, et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. Langenbecks Arch Surg. 2013;398:239\u201349.","journal-title":"Langenbecks Arch Surg"},{"key":"17601_CR28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10120-020-01098-w","volume":"24","author":"K Fujitani","year":"2021","unstructured":"Fujitani K, Nakamura K, Mizusawa J, et al. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A. Gastric Cancer. 2021;24:197\u2013204.","journal-title":"Gastric Cancer"},{"key":"17601_CR29","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1200\/JCO.2015.65.7692","volume":"34","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Fassan M, Cunningham D, et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol. 2016;34:2721\u20137.","journal-title":"J Clin Oncol"},{"key":"17601_CR30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.21147\/j.issn.1000-9604.2018.05.01","volume":"30","author":"J Deng","year":"2018","unstructured":"Deng J, Liu J, Wang W, et al. Validation of clinical significance of examined lymph node count for accurate prognostic evaluation of gastric cancer for the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system. Chin J Cancer Res. 2018;30:477\u201391.","journal-title":"Chin J Cancer Res"},{"key":"17601_CR31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40364-021-00306-8","volume":"9","author":"CC Ko","year":"2021","unstructured":"Ko CC, Yeh LR, Kuo YT, et al. Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomark Res. 2021;9:52.","journal-title":"Biomark Res"},{"key":"17601_CR32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"key":"17601_CR33","doi-asserted-by":"crossref","first-page":"726492","DOI":"10.3389\/fimmu.2021.726492","volume":"12","author":"CR Stoltzfus","year":"2021","unstructured":"Stoltzfus CR, Sivakumar R, Kunz L, et al. Multi-parameter quantitative imaging of tumor microenvironments reveals perivascular immune niches associated with anti-tumor immunity. Front Immunol. 2021;12:726492.","journal-title":"Front Immunol"},{"key":"17601_CR34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1097\/JS9.0000000000001022","volume":"110","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zheng H, Jiang ST, et al. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis. Int J Surg. 2024;110:1699\u2013710.","journal-title":"Int J Surg"},{"key":"17601_CR35","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","volume":"30","author":"AJ Widman","year":"2024","unstructured":"Widman AJ, Shah M, Frydendahl A, et al. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024;30:1655\u201366.","journal-title":"Nat Med"},{"key":"17601_CR36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda MA, Janku F, Wahida A, et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann Oncol. 2024;35:267\u201375.","journal-title":"Ann Oncol"},{"key":"17601_CR37","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510\u20137.","journal-title":"J Clin Oncol"},{"key":"17601_CR38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10120-003-0240-9","volume":"6","author":"Y Takahashi","year":"2003","unstructured":"Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and\/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142\u20135.","journal-title":"Gastric Cancer"},{"key":"17601_CR39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.","journal-title":"J Hematol Oncol"},{"key":"17601_CR40","doi-asserted-by":"crossref","first-page":"e154941","DOI":"10.1172\/JCI154941","volume":"132","author":"DK Dang","year":"2022","unstructured":"Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Investig. 2022;132:e154941.","journal-title":"J Clin Investig"},{"key":"17601_CR41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223\u201338.","journal-title":"Nat Rev Cancer"},{"key":"17601_CR42","doi-asserted-by":"crossref","first-page":"e005344","DOI":"10.1136\/jitc-2022-005344","volume":"11","author":"PJ Vellanki","year":"2023","unstructured":"Vellanki PJ, Ghosh S, Pathak A, et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023;11:e005344.","journal-title":"J Immunother Cancer"},{"key":"17601_CR43","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/annonc\/mdz196","volume":"30","author":"P Hofman","year":"2019","unstructured":"Hofman P, Heeke S, Alix-Panabi\u00e8res C, et al. Liquid biopsy in the era of immuno-oncology: Is it ready for prime-time use for cancer patients? Ann Oncol. 2019;30:1448\u201359.","journal-title":"Ann Oncol"},{"key":"17601_CR44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/PO.19.00386","volume":"4","author":"MM Frigault","year":"2020","unstructured":"Frigault MM, Markovets A, Nuttall B, et al. Mechanisms of acquired resistance to savolitinib, a selective MET inhibitor in MET-amplified gastric cancer. JCO Precis Oncol. 2020;4:222\u201332.","journal-title":"JCO Precis Oncol"},{"key":"17601_CR45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12935-024-03209-4","volume":"24","author":"JH Li","year":"2024","unstructured":"Li JH, Zhang DY, Zhu JM, et al. Clinical applications and perspectives of circulating tumor DNA in gastric cancer. Cancer Cell Int. 2024;24:13.","journal-title":"Cancer Cell Int"},{"key":"17601_CR46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41419-022-05350-2","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wu H, Chong W, et al. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers. Cell Death Dis. 2022;13:903.","journal-title":"Cell Death Dis"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17601-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:02:09Z","timestamp":1754150529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17601-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["17601"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17601-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"All procedures followed were by the ethical standards of the committees responsible for human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}